Law360 (July 30, 2020, 10:44 PM EDT) -- A California federal judge expressed "a lot of concerns" Thursday about the adequacy of Tevra Brands LLC's $114 million pet medication antitrust complaint against Bayer, saying she's hesitant to "open up the floodgates of what will be enormously expensive discovery."
During a hearing held via Zoom, U.S. District Judge Beth Freeman doubted whether the generic pet medication company's antitrust complaint sufficiently defines the market that Bayer HealthCare LLC allegedly monopolizes. She noted that there appear to be different types of pet flea and tick medication products involved — one being a flea collar and another being a topical treatment.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!